218 results on '"Somford, D.M."'
Search Results
2. Evaluation of the minimum volume standard for radical prostatectomies in the Netherlands: Centralization of care and surgical outcomes over time
3. Prostate-specific antigen density (PSAD) in post-magnetic resonance imaging (MRI) risk-stratification to avoid biopsies and detection of low-risk prostate cancer: Results of the MR-PROPER study
4. Risk for progression in patients with pathological lymph-node metastatic disease (pN1) who underwent robot-assisted radical prostatectomy and extensive pelvic lymph node dissection.
5. Pre-magnetic resonance imaging (MRI) prostate-specific antigen density (PSAD) risk-stratification to avoid MRIs, biopsies and detection of low-risk prostate cancer: Results of the MR-PROPER study
6. Rectal culture-based versus empirical antibiotic prophylaxis to prevent infectious complications in men undergoing transrectal prostate biopsy: A randomized, non-blinded multicenter trial
7. Diagnostic performance of 18F-rhPSMA-7.3 PET in men with newly diagnosed unfavourable intermediate to very high-risk prostate cancer: Results from the phase 3 LIGHTHOUSE study
8. Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trial.
9. Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry.
10. Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome
11. Cost Effectiveness of Rectal Culture-based Antibiotic Prophylaxis in Transrectal Prostate Biopsy: The Results from a Randomized, Nonblinded, Multicenter Trial.
12. The effect of a reduced dose of enzalutamide on fatigue and cognition
13. Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
14. Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor-Darolutamide.
15. Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand.
16. Reply to Francesco Montorsi, Simone Scuderi, Alberto Briganti, and Giorgio Gandaglia's Letter to the Editor re: Melline G.M. Schilham, Mark Rijpkema, Tom Scheenen, et al. How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come. Eur Urol 2022;82:578-80
17. Correlation of claims based and patient reported pad use for incontinence one year after radical prostatectomy
18. Corrigendum to “Urinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: A nationwide observational study”
19. Optimization of Preoperative Lymph Node Staging in Patients with Muscle-Invasive Bladder Cancer Using Radiomics on Computed Tomography
20. Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands
21. Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection
22. Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer
23. The Effect of Different Types of Prostate Biopsy Techniques on Post-Biopsy Infectious Complications
24. How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come
25. Lymph node staging with 18F-PSMA-1007 PET/CT in newly diagnosed prostate cancer using histopathological evaluation as a reference
26. Feasibility of radio-guided lymph node dissection in primary oligometastatic prostate cancer patients: An interim analysis
27. Evaluating confocal laser microscopy to assess intraoperative surgical margin status of prostatectomy specimen, a feasibility study (ENCLOSURE-1)
28. P134 - Risk for progression in patients with pathological lymph-node metastatic disease (pN1) who underwent robot-assisted radical prostatectomy and extensive pelvic lymph node dissection.
29. P010 - Prostate-specific antigen density (PSAD) in post-magnetic resonance imaging (MRI) risk-stratification to avoid biopsies and detection of low-risk prostate cancer: Results of the MR-PROPER study
30. O05 - Pre-magnetic resonance imaging (MRI) prostate-specific antigen density (PSAD) risk-stratification to avoid MRIs, biopsies and detection of low-risk prostate cancer: Results of the MR-PROPER study
31. Radicale prostatectomie in Nederland
32. Lymph node staging with 18F-PSMA-1007 PET/CT in newly diagnosed prostate cancer using histopathological evaluation as a reference
33. Impact of peri-operative testosterone levels on oncological and functional outcomes in radical prostatectomy (ENFORCE trial)
34. Preoperative PSMA PET/CT as a predictor of biochemical persistence and early biochemical recurrence
35. Radio-guided lymph node dissection in primary oligometastatic prostate cancer patients
36. Diagnostic accuracy of 18F-fluciclovine PET/CT in primary lymph node staging of prostate cancer
37. RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
38. The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population
39. Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study
40. Variation in the Prescription of Androgen Deprivation Therapy in Intermediate- and High-risk Prostate Cancer Patients Treated with Radiotherapy in the Netherlands, and Adherence to European Association of Urology Guidelines: A Population-based Study
41. Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment
42. Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry
43. 1823P The impact of baseline PSMA PET/CT vs. CT on outcomes of Radium-223 therapy in mCRPC patients
44. mpMRI based targeted biopsy of the prostate: Is there a preferred technique?
45. Implementation of a decision aid for localized prostate cancer in routine care: A successful implementation strategy
46. Is There Still a Need for Repeated Systematic Biopsies in Patients with Previous Negative Biopsies in the Era of Magnetic Resonance Imaging-targeted Biopsies of the Prostate?
47. Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer
48. Urinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: A nationwide observational study
49. Prostate biopsy techniques and pre-biopsy prophylactic measures: variation in current practice patterns in the Netherlands
50. Introducing decision aids into routine prostate cancer care in the Netherlands: Implementation and patient evaluations from the multi-regional JIPPA initiative
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.